Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations

Guidance clarifying the requirements of FDA regulations on human subject protection (21 CFR part 50) and IRBs (21 CFR part 56) and the Department of Health and Human Services' Federal Policy for Protection of Human Research Subjects (45 CFR 46, Subpart A; “the Common Rule”).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/32zWZfh